Do analysts rate HVO or CIR?

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts clearly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TILS or HVO?

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts prefer HVO or VSN?

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than Verseon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Verseon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, HVO or VSN?

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £38.85M 1.04 £17.84M -£1.78 N/A Verseon N/A N/A N/A -£14.30 N/A

Is HVO or VSN more profitable?

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -31.76%. Verseon's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -31.76% -35.13% 11.97% Verseon N/A N/A N/A

Do analysts rate HVO or SCLP?

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts plainly believe hVIVO is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, HVO or SCLP?

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £38.85M 1.04 £17.84M -£1.78 N/A Scancell £4.71M 21.31 -£6.75M -£0.55 N/A

Is HVO or SCLP more profitable?

hVIVO has a net margin of -31.76% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -31.76% -35.13% 11.97% Scancell -116.98% 90.29% -45.28%

Do analysts rate MPH or HVO?

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Mereo BioPharma Group plc (MPH.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group plc (MPH.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

hVIVO (HVO) Competitors

GBX 5.94 +0.05 (+0.76%)

As of 04:24 AM Eastern

Compare

HVO vs. CIR, TILS, VSN, SCLP, and MPH

Should you buy hVIVO stock or one of its competitors? hVIVO's main competitors and comparable companies include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), and Mereo BioPharma Group plc (MPH.L) (MPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Circassia Group?

hVIVO (LON:HVO) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£38.85M	1.04	£17.84M	-£1.78	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -31.76%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-31.76%	-35.13%	11.97%
Circassia Group	N/A	N/A	N/A

12.7% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, research analysts clearly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, hVIVO had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Circassia Group. hVIVO's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Circassia Group	Neutral

Summary

hVIVO beats Circassia Group on 8 of the 12 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, hVIVO had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
hVIVO	Neutral

12.7% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -31.76%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
hVIVO	-31.76%	-35.13%	11.97%

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
hVIVO	£38.85M	1.04	£17.84M	-£1.78	N/A

hVIVO has a consensus price target of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

hVIVO beats Tiziana Life Sciences on 10 of the 12 factors compared between the two stocks.

How does hVIVO compare to Verseon?

hVIVO (LON:HVO) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

12.7% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

hVIVO has higher revenue and earnings than Verseon. hVIVO is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£38.85M	1.04	£17.84M	-£1.78	N/A
Verseon	N/A	N/A	N/A	-£14.30	N/A

In the previous week, hVIVO had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Verseon. hVIVO's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Verseon	Neutral

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than Verseon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Verseon	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Verseon has a net margin of 0.00% compared to hVIVO's net margin of -31.76%. Verseon's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-31.76%	-35.13%	11.97%
Verseon	N/A	N/A	N/A

Summary

hVIVO beats Verseon on 10 of the 12 factors compared between the two stocks.

How does hVIVO compare to Scancell?

hVIVO (LON:HVO) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 13.2% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

hVIVO has a beta of 1.694, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Scancell has a beta of 0.685, suggesting that its share price is 32% less volatile than the broader market.

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts plainly believe hVIVO is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has a net margin of -31.76% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-31.76%	-35.13%	11.97%
Scancell	-116.98%	90.29%	-45.28%

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£38.85M	1.04	£17.84M	-£1.78	N/A
Scancell	£4.71M	21.31	-£6.75M	-£0.55	N/A

In the previous week, hVIVO had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Scancell. hVIVO's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Scancell	Neutral

Summary

hVIVO beats Scancell on 11 of the 15 factors compared between the two stocks.

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

hVIVO has higher revenue and earnings than Mereo BioPharma Group plc (MPH.L). hVIVO is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A	-£128.00	N/A
hVIVO	£38.85M	1.04	£17.84M	-£1.78	N/A

hVIVO has a consensus target price of GBX 15, indicating a potential upside of 154.80%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Mereo BioPharma Group plc (MPH.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group plc (MPH.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to hVIVO's net margin of -31.76%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group plc (MPH.L)	N/A	N/A	N/A
hVIVO	-31.76%	-35.13%	11.97%

In the previous week, hVIVO had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Mereo BioPharma Group plc (MPH.L)	Neutral
hVIVO	Neutral

Summary

hVIVO beats Mereo BioPharma Group plc (MPH.L) on 9 of the 12 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£41.30M	£3.85B	£7.14B	£2.84B
Dividend Yield	2.68%	3.65%	2.53%	6.26%
P/E Ratio	-3.37	12.99	274.34	366.82
Price / Sales	1.06	1,293.73	614.18	89,165.41
Price / Cash	4.94	39.04	27.22	27.89
Price / Book	1.08	17.34	11.34	7.08
Net Income	£17.84M	-£23.20M	£3.49B	£5.89B
7 Day Performance	-4.31%	-2.11%	-1.27%	-0.49%
1 Month Performance	-10.71%	-10.19%	-5.94%	-0.99%
1 Year Performance	-14.29%	17.45%	7.29%	23.00%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	1.2347 of 5 stars	GBX 5.95 +0.8%	GBX 15 +152.3%	-19.4%	£40.93M	£38.85M	N/A	N/A	Gap Up
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11
VSN Verseon	N/A	N/A	N/A	N/A	£112.24M	N/A	N/A	N/A	Gap Up
SCLP Scancell	N/A	GBX 9.37 -0.3%	N/A	-3.1%	£100.04M	£4.71M	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. CIR, TILS, VSN, SCLP, and MPH

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

How does hVIVO compare to Verseon?

Summary

How does hVIVO compare to Scancell?

Summary

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. CIR, TILS, VSN, SCLP, and MPH

How does hVIVO compare to Circassia Group?

Which has stronger valuation & earnings, HVO or CIR?

Is HVO or CIR more profitable?

Do insiders and institutionals have more ownership in HVO or CIR?

Do analysts rate HVO or CIR?

Does the media favor HVO or CIR?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Does the media refer more to TILS or HVO?

Do institutionals and insiders believe in TILS or HVO?

Is TILS or HVO more profitable?

Which has stronger valuation and earnings, TILS or HVO?

Do analysts rate TILS or HVO?

Summary

How does hVIVO compare to Verseon?

Do institutionals and insiders hold more shares of HVO or VSN?

Which has stronger earnings and valuation, HVO or VSN?

Does the media prefer HVO or VSN?

Do analysts prefer HVO or VSN?

Is HVO or VSN more profitable?

Summary

How does hVIVO compare to Scancell?

Do insiders & institutionals believe in HVO or SCLP?

Which has more volatility and risk, HVO or SCLP?

Do analysts rate HVO or SCLP?

Is HVO or SCLP more profitable?

Which has better valuation and earnings, HVO or SCLP?

Does the media refer more to HVO or SCLP?

Summary

How does hVIVO compare to Mereo BioPharma Group plc (MPH.L)?

Do institutionals and insiders have more ownership in MPH or HVO?

Which has stronger valuation and earnings, MPH or HVO?

Do analysts rate MPH or HVO?

Is MPH or HVO more profitable?

Does the media prefer MPH or HVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools